-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LGf9uERZ0PyiIPFaFZubSRU1M0+vDF0afKEK5m1GDUdMjWzysYonfRR5Je9JNMct KevJ1pu71sQ2qYwSH+z9MA== 0000872947-08-000006.txt : 20080407 0000872947-08-000006.hdr.sgml : 20080407 20080407092442 ACCESSION NUMBER: 0000872947-08-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080402 ITEM INFORMATION: Other Events FILED AS OF DATE: 20080407 DATE AS OF CHANGE: 20080407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED NEUROSOLUTIONS INC CENTRAL INDEX KEY: 0000872947 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 391661164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13835 FILM NUMBER: 08741908 BUSINESS ADDRESS: STREET 1: 50 LAKEVIEW PARKWAY S STREET 2: STE 111 CITY: VERNON HILLS STATE: IL ZIP: 60061 BUSINESS PHONE: 847 573 8000 MAIL ADDRESS: STREET 1: 50 LAKEVIEW PARKWAY STREET 2: STE 111 CITY: VERNON HILLS STATE: IL ZIP: 60061 FORMER COMPANY: FORMER CONFORMED NAME: HEMOXYMED INC DATE OF NAME CHANGE: 20020820 FORMER COMPANY: FORMER CONFORMED NAME: OPHIDIAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970714 8-K 1 form8klillymilelstone4208.htm FORM 8K LILLY MILESTONE 4/2/08 form8klillymilelstone4208.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K

 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 
Date of Report (Date of earliest event reported)    April 2, 2008
 
APPLIED NEUROSOLUTIONS, INC.
(Exact name of Registrant as Specified in its Charter)
 



  Delaware                                                   001-13835                                      39-1661164
 (State or Other Jurisdiction             (Commission file Number)            (IRS Employer
       of  Incorporation)                                                                               Identification No.)
 
    50 Lakeview Parkway, Suite 111, Vernon Hills, IL                                   60061
(Address of Principal Executive Offices)                                             (Zip Code)
 
Registrant’s telephone number, including area code (847) 573-8000
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 

 
 
 

 
Section 8       –    Other Events
 
   Item 8.01.
Other Events
 
 
The Registrant today announced the attainment of a program milestone in its collaboration with Eli Lilly and Company (Lilly) to develop therapeutics to treat Alzheimer’s disease (AD).  Attainment of this milestone supports the continuation of the Registrant’s collaboration with Lilly.
 
 
 In November 2006, the Registrant entered into an agreement with Lilly to develop therapeutics to treat AD.  Lilly has been funding the vast majority of all pre-clinical research and development and will fully finance the clinical testing, manufacturing, sales and marketing of AD therapeutics developed from this collaboration.  The Applied NeuroSolutions, Inc. (APNS) proprietary tau-related target has now achieved two significant unpaid program milestones.  The next milestone, if achieved, represents a paid milestone for APNS.  The next milestone is currently targeted for achievement in late 2008 to early 2009.  The collaboration with Lilly continues to make good progress toward additional tau-based targets with an additional target being screened and validation studies underway for other targets.
 




 
1 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 7th day of April 2008.
APPLIED NEUROSOLUTIONS, INC.
 
By:           /s/David Ellison                                 
Name:   David Ellison
Title:     Chief Financial Officer


 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 

 -----END PRIVACY-ENHANCED MESSAGE-----